As of press time, the stock rose more than 5.4%, reaching $12.57.
According to the Futu Finance app, on Friday, vaccine concept stocks had mixed performance. The stock price of Novavax (NVAX.US) rose and as of press time, it rose more than 5.4%, reaching $12.57. The company stated that its updated COVID-19 vaccine has been approved for use in the US, targeting individuals aged 12 and above.
Moderna (MRNA.US) fell nearly 4%, reaching $66.92. Moderna plans to launch an mRNA-based skin cancer vaccine as early as next year. It is reported that Moderna has released mid-term data for its personalized cancer vaccine, mRNA-4157, which is combined with Merck's (MRK.US) PD-1 therapy Keytruda for the treatment of melanoma. Pfizer (PFE.US) experienced a slight decline of 0.22%.